Cited by 333Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and ManagementCancer Genomics and Diagnostics

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Open access

Lee, J.H., Long, G.V., Boyd, S., Lo, S., Menzies, A.M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R.A., Mann, G.J., Kefford, R.F., Carlino, M.S., Rizos, H.·2017·Annals of Oncology

DOI 10.1093/annonc/mdx026

Open this paper in CoChat — free account Open PDF

Abstract

Background Programmed death 1 (PD1) inhibitors are now a foundation of medical management of metastatic melanoma. This study sought to determine whether circulating tumour DNA (ctDNA) provides useful early response and prognostic information.Patients and methods We evaluated the relationship between pre-treatment and early on treatment ctDNA and outcome in melanoma patients treated with PD1 inhibitors alone or in combination with ipilimumab.Results ctDNA was detected in 40/76 patients (53%) at baseline, and correlated with stage, LDH levels, disease volume and ECOG performance. RECIST response was 72% (26/36) in group A (undetectable ctDNA at baseline), 77% (17/22) in group B (elevated ctDNA at baseline but undetectable within 12 weeks of therapy) and 6% (1/18) in group C (elevated ctDNA at baseline and remained elevated during treatment). The median PFS was not reached in groups A and B and was 2.7 months for group C [hazard ratio (HR) 0.09; P < 0.001 for group A versus C, and 0.16; P < 0.001 for group B versus C]. The median OS was not reached for groups A and B and was 9.2 months for group C (HR 0.02; P < 0.001 for group A versus C and 0.14; P < 0.001 for group B versus C). The poor outcome measures associated with group C remained significant in multivariate analysis adjusted for LDH, performance status, tumour stage and disease volume. The predictive value for ctDNA for response was confirmed in a separate validation cohort (n = 29, P < 0.01).Conclusion Longitudinal assessment of ctDNA in metastatic melanoma patients receiving treatment with PD1 inhibitors is an accurate predictor of tumour response, PFS and OS. Patients who had a persistently elevated ctDNA on therapy had a poor prognosis, and this may guide combination and sequencing of subsequent therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1093/annonc/mdx026

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citation
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citation
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citation
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590
Absolute quantification by droplet digital PCR versus analog real-time PCR
Hindson, C. M., Chevillet, J. R., Briggs, H. A., Gallichotte, E. N., Ruf, I. K., Hindson, B. J., Vessella, R. L., & Tewari, M. (2013) · Nature Methods · doi:10.1038/nmeth.2633 · Cited by 1,488

Show all 25 references

Sorted by citations

Items 301–333 of 333

A Complete Response in a Metastatic Melanoma Patient After a Single Dose of Dual Checkpoint Inhibitors Blockade Could Be Predictable: A Case Report
Mihăilă, R. I., Gheorghe, A. S., Zob, D., & Stănculeanu, D. L. (2024) · Cureus · doi:10.7759/cureus.69301
The Role of Lymphocytic Infiltrates in the Tumor Microenvironment as a Predictive Factor for the Response to Immunotherapy in Solid Tumors: A Single-Center Experience From Romania
Mihăilă, R. I., Gheorghe, A. S., Zob, D., & Stănculeanu, D. L. (2024) · Cureus · doi:10.7759/cureus.74194
Advances in blood microsampling technology for cancer biomarker detection
Lucas, N., Herbert, B. R., & Molloy, M. P. (2025) · Advances in clinical chemistry · doi:10.1016/bs.acc.2025.04.005
Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma
Bobak, K., Synoradzki, K. J., Sulejczak, D., Rutkowski, P. L., & Czarnecka, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_179
Immune Checkpoint Blockade Response Biomarkers
Garrido-Barros, M., Cháves, P., & Barragán, I. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_160
Machine learning‐derived serum protein signatures as biomarkers for checkpoint inhibition in melanoma
Schaper‐Gerhardt, K., Flatt, N., Rana, U., Walter, A., Oostermann, B., Angela, Y., DeTemple, V. K., Kochanek, C., Borggrefe, J., von Wasielewski, I., et al. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70201
Additional file 3 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G.-R. (2023) · Figshare · doi:10.6084/m9.figshare.24144112
Additional file 5 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G.-R. (2023) · Figshare · doi:10.6084/m9.figshare.24144118
Additional file 6 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G.-R. (2023) · Figshare · doi:10.6084/m9.figshare.24144121
Additional file 8 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G.-R. (2023) · Figshare · doi:10.6084/m9.figshare.24144127
Additional file 2 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G.-R. (2023) · Figshare · doi:10.6084/m9.figshare.24144109
Additional file 9 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G.-R. (2023) · Figshare · doi:10.6084/m9.figshare.24144130
Additional file 4 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G.-R. (2023) · Figshare · doi:10.6084/m9.figshare.24144115
Additional file 7 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G. (2023) · Figshare · doi:10.6084/m9.figshare.24144124
Additional file 1 of Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer
Peng, W.-W., Liu, Y., Sha, H.-H., Wen, S.-D., Fang, Y., & Zhou, G. (2023) · Figshare · doi:10.6084/m9.figshare.24144103
Circulating Transcriptome Analysis Finds Gene Signatures and Immune Cell Activation and Abundance Predict Response to Immunotherapy in Bladder Cancer
Chevrier, S., Richard, C., Adotévi, O., Ayyoub, M., Chaput, N., Damotte, D., Ghiringhelli, F., Hacein‐Bey‐Abina, S., Tartour, É., Zitvogel, L., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2306
Development of a Nomogram to Predict Therapeutic Resistance in Metastatic Melanoma Using Longitudinal ctDNA Kinetics
Miller, H. A., Fischer, A. G., Egger, M. E., Yaddanapudi, K., Kong, M., Hall, M. B., & Linder, M. W. (2026) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-026-00840-x
L'expression d'HVEM est complémentaire à celle de PD-L1 dans le mélanome à la fois en terme d'expression et de régulation et est un facteur de mauvais pronostic faisant d'HVEM une cible thérapeutique potentielle dans le mélanome
Malissen, N. (2018) · theses.fr (ABES) · doi:10.70675/6e683c4ez28c0z442azaf6az7efb18488bc9
Evaluation de l'ADN circulant tumoral (ADNct) comme biomarqueur de réponse aux thérapies ciblées développées en phase précoce en oncologie
Frenel, J. (2018) · doi:10.70675/5f8e882fz8672z4e65zb2d7z52ac604f3c9b
Détection et quantification de l'ADN circulant : conditions pré-analytiques et applications pour le suivi des patients atteints de cancer colorectal
Meddeb, R. (2019) · theses.fr (ABES) · doi:10.70675/43aaefbdz9b84z4530z9f7az31734d0d3d36
ADN tumoral circulant : aspects analytiques et intérêt dans la prise en charge des patients atteints de mélanome cutané métastatique
Herbreteau, G. (2020) · theses.fr (ABES) · doi:10.70675/8db97ab9zf3b5z4de3za6ccz9d08aa2ef35c
Gut microbiota-related biomarkers in immuno-oncology
Silva, C. A. C. (2023) · theses.fr (ABES) · doi:10.70675/9022496ez0bbbz4f94z9760z4ae0a6ee5e7a
Clinical and Radiometabolic Correlatives of ddPCR Liquid Biopsy for BRAF V600 Mutated Melanoma
Stoff, R., Bilgin, G. B., Nikanpour, Y., Johnson, G. B., Kipp, B. R., Zahrieh, D. M., Geiersbach, K. B., Block, M. S., & Markovic, S. N. (2026) · International Journal of Cancer · doi:10.1002/ijc.70514
Multimodal data fusion: integrating PET/MRI and liquid biopsy for a holistic view of cancer biology
Zhao, Y., Shen, B., Luo, W., & Wang, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1775271
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy Response
Lawless, A. R., Effiom, D. N., Burbano, A. V., Sharova, T., Otten, T. J., Basnet, M., Spurr, E., Shankar, T., Crespo, M. C., Czapla, J. A., et al. (2026) · Annals of Surgical Oncology · doi:10.1245/s10434-026-19814-8
Association of Circulating Tumor DNA With Brain Metastases: A Systematic Review and Meta‐Analysis
Yang, S., Zhang, Z., Dong, H., Yu, X., Zhu, F., & Shun, Y. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70965
Imaging in Cutaneous Melanoma: Current Workup, Surveillance, and Emerging Directions
Willem, H., Aguilar, T., Cowman, A. W., Lourdault, K., & Essner, R. (2026) · Cancers · doi:10.3390/cancers18142215
Case Report: Exceptional response to perioperative pembrolizumab in UV-signature melanoma of unknown primary presenting as an isolated pulmonary metastasis
Drysch, A. P., Gjyzeli, G., Buttars, P. R., Chandra, S., & Lung, K. C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1860040
Current and emerging strategies for the management of brain and leptomeningeal metastases in melanoma
Idoudi, S., Karine, B., Ezine, E., Fournier, M., Norri, N., Decq, P., Goutagny, S., Nataf, F., Lebbé, C., & Faillot, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1874139
Omics-Nano-CRISPR Strategies for Combating Skin Cancer in the AI Age
Chauhan, A. S., Durgapal, S., Pandit, J., & Raghav, A. (2026) · IGI Global eBooks · doi:10.4018/979-8-3373-9715-3.ch009
Vitiligo-like depigmentation as an accessible readout of antitumour immunity in melanoma immunotherapy
Toshev, S., Jalalova, D., Tastanova, G., Nurmatova, I., Latipov, I., & Ismoilov, O. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04584-2
Cellular origins and evolutionary dynamics of plasma cfDNA in solid tumors: integrating germline, tumor-derived, and hematopoietic variation for MRD and treatment guidance
Zhao, Q., Wu, C., Huang, X., Yang, M., & Zhang, B. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1928945
Emerging immunotherapies in melanoma beyond immune checkpoint inhibitors: Vaccines, intralesional therapies, adoptive cell therapies, and T-cell engagers
Taglialatela, I., Corcia, L. D., Boutros, A., Gatti, A., Sponghini, A. P., Esposto, E., Farinelli, P., Giorgione, R., Zottarelli, F., Zavattaro, E., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101482

Authors: Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., Kefford, R. F., Carlino, M. S., & Rizos, H.
Affiliations: The University of Sydney (AU)
Macquarie University (AU)
Melanoma Institute Australia (AU)
Royal Prince Alfred Hospital (AU)
Corresponding author: Rizos, H.
ORCID: Lee, J.H.
Long, G.V.
Lo, S.
Menzies, A.M.
Guminski, A.
Jakrot, V.
Scolyer, R.A.
Mann, G.J.
Kefford, R.F.
Carlino, M.S.
Rizos, H.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2017-05
Volume: 28
Issue: 5
Pages: 1130-1136
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1093/annonc/mdx026
OpenAlex: W2588078993
Cited by: 333
References: 25
Citations by year: 2026: 22 · 2025: 21 · 2024: 16 · 2023: 52 · 2022: 28 · 2021: 51 · 2020: 48 · 2019: 43 · 2018: 39 · 2017: 12
FWCI: 17.23
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 917 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: National Health and Medical Research Council (1093017 and 1130423)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: circulating tumor DNA, metastatic melanoma, PD-1 inhibitors, ipilimumab, treatment response prediction, prognostic factors, progression-free survival, overall survival, longitudinal ctDNA monitoring, immune checkpoint inhibitors
MeSH terms: Circulating Tumor DNA, Ipilimumab, Aged, Antibodies, Anti-Idiotypic, Female, Humans, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Biomarkers, Tumor, Neoplasms, Second Primary, Disease-Free Survival, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks